{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:11:33Z","timestamp":1761808293908,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.cjca.2019.06.022","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T12:01:43Z","timestamp":1561550503000},"page":"1686-1697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Fran\u00e7ois-Pierre","family":"Mongeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Macle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc M.","family":"Beauchesne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berto J.","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Schwerzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Khairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.06.022_bib1","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1586\/14779072.2013.854703","article-title":"Thrombosis in congenital heart disease","volume":"11","author":"Khairy","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2019.06.022_bib2","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.hrthm.2014.05.009","volume":"11","author":"Khairy","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2019.06.022_bib3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jacc.2018.08.1028","article-title":"2018 AHA\/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Stout","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/hrt.2010.196147","article-title":"Cerebrovascular accidents in adult patients with congenital heart disease","volume":"96","author":"Hoffmann","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2019.06.022_bib5","doi-asserted-by":"crossref","unstructured":"Huynh K. Milestone 10: era of the NOACs [e-pub ahead of print]. Nat Rev Cardiol https:\/\/doi.org\/10.1038\/nrcardio.2017.180, accessed February 12, 2018.","DOI":"10.1038\/nrcardio.2017.180"},{"key":"10.1016\/j.cjca.2019.06.022_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.022_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-018-0107-0","article-title":"A\u00a0review of the role of non-vitamin K oral anticoagulants in the acute and long-term treatment of venous thromboembolism","volume":"7","author":"Bromley","year":"2018","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.cjca.2019.06.022_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran vs warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.amjcard.2015.11.002","article-title":"The use of novel oral anticoagulants in adult congenital heart disease: a single center experience","volume":"117","author":"Cheng","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/chd.12603","article-title":"Novel oral anticoagulant use in adult Fontan patients: a single center experience","volume":"13","author":"Georgekutty","year":"2018","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.cjca.2019.06.022_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2014.12.101","article-title":"Thrombosis in Fontan patient on apixaban","volume":"182","author":"Pinto","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.amjcard.2015.10.062","article-title":"Usefulness of direct oral anticoagulants in adult congenital heart disease","volume":"117","author":"Pujol","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10557-017-6745-y","article-title":"Is initiating NOACs for atrial arrhythmias safe in adults with congenital heart disease?","volume":"31","author":"Yang","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2019.06.022_bib14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2019.06.022_bib15","first-page":"1597","article-title":"Anticoagulation for thromboembolic risk reduction in adults with congenital heart disease","volume":"33","author":"Wan","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2017.02.004","article-title":"Increased risk of thromboembolic events in adult congenital heart disease patients with atrial tachyarrhythmias","volume":"234","author":"Masuda","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib17","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/CIRCULATIONAHA.109.866319","article-title":"Atrial arrhythmias in adults with congenital heart disease","volume":"120","author":"Bouchardy","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2019.01.079","article-title":"Atrial fibrillation in adults with congenital heart disease","volume":"287","author":"Waldmann","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijcard.2015.02.024","article-title":"Weighing the risks: thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease","volume":"186","author":"Heidendael","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ijcard.2016.08.223","article-title":"Thromboprophylaxis for atrial arrhythmias in congenital heart disease: a multicenter study","volume":"223","author":"Khairy","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.107.738559","article-title":"Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery","volume":"117","author":"Khairy","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib22","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/eurheartj\/ehq356","article-title":"Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients","volume":"31","author":"Diller","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib23","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2015.07.065","article-title":"40-Year follow-up after the Fontan Operation: long-term outcomes of 1,052 patients","volume":"66","author":"Pundi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib24","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","article-title":"Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association","volume":"128","author":"Giglia","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacc.2012.08.1023","article-title":"Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure","volume":"61","author":"McCrindle","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib26","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jacc.2016.06.050","article-title":"Fontan anticoagulation: a never-ending debate?","volume":"68","author":"Balling","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1136\/heartjnl-2015-307657","article-title":"Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease","volume":"101","author":"Jensen","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2019.06.022_bib28","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2003.07.022","article-title":"Pulmonary thrombosis in adults with Eisenmenger syndrome","volume":"42","author":"Silversides","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0735-1097(99)00153-9","article-title":"Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart","volume":"34","author":"Niwa","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jacc.2007.04.056","article-title":"Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity","volume":"50","author":"Broberg","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9149(03)00535-6","article-title":"Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension","volume":"92","author":"Perloff","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib32","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1053\/euhj.1998.1046","article-title":"Eisenmenger syndrome. Factors relating to deterioration and death","volume":"19","author":"Daliento","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/157340310793566127","article-title":"The adult patient with Eisenmenger syndrome: a medical update after Dana Point Part III: specific management and surgical aspects","volume":"6","author":"Oechslin","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.cjca.2019.06.022_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehv743","article-title":"Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects","volume":"37","author":"Diller","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1747-0803.2012.00633.x","article-title":"Does anticoagulation in Eisenmenger syndrome impact long-term survival?","volume":"7","author":"Sandoval","year":"2012","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.cjca.2019.06.022_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0735-1097(96)00196-9","article-title":"Cerebrovascular events in adult patients with cyanotic congenital heart disease","volume":"28","author":"Ammash","year":"1996","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003596","article-title":"Impaired right, left, or biventricular function and resting oxygen saturation are associated with mortality in Eisenmenger syndrome: a clinical and cardiovascular magnetic resonance study","volume":"8","author":"Jensen","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.06.022_bib38","first-page":"689","article-title":"Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism","volume":"11","author":"Perloff","year":"1993","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.cjca.2019.06.022_bib39","doi-asserted-by":"crossref","first-page":"k2515","DOI":"10.1136\/bmj.k2515","article-title":"Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline","volume":"362","author":"Kuijpers","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2019.06.022_bib40","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.113.003540","article-title":"Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale","volume":"128","author":"DeSimone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib41","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1161\/CIRCULATIONAHA.106.622076","article-title":"Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study","volume":"113","author":"Khairy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib42","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/ATVBAHA.117.306995","article-title":"Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective","volume":"37","author":"Hoffman","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2019.06.022_bib43","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cjca.2019.06.022_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib45","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2019.06.022_bib46","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","article-title":"Non-vitamin K antagonist oral anticoagulants for mechanical heart valves","volume":"138","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban vs warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib49","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban vs warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran vs warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban vs warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib52","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ehjcvp\/pvx028","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"4","author":"Caldeira","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjca.2019.06.022_bib55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/heartjnl-2017-312272","article-title":"Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease","volume":"104","author":"Vinereanu","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2019.06.022_bib56","article-title":"Effects of non-vitamin K antagonist oral anticoagulants vs warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2019.06.022_bib57","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib58","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib59","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib61","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jchf.2016.07.012","article-title":"Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis","volume":"4","author":"Savarese","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2019.06.022_bib62","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ejhf.343","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials","volume":"17","author":"Xiong","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2019.06.022_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hrthm.2016.12.036","article-title":"Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants","volume":"14","author":"Park","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2019.06.022_bib64","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.107.734921","article-title":"Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease","volume":"117","author":"Dimopoulos","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib65","first-page":"860","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib66","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib68","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1161\/CIR.0000000000000535","article-title":"Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association","volume":"136","author":"Lui","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib69","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(16)30111-9","article-title":"Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series","volume":"3","author":"Beyer-Westendorf","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cjca.2019.06.022_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.cjca.2019.06.022_bib71","first-page":"1486","article-title":"New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation","volume":"70","author":"Chatterjee","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cjca.2019.06.022_bib72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjca.2019.06.022_bib73","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.022_bib74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2017.09.029","article-title":"Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: propensity score matched cohort study","volume":"249","author":"Denas","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib75","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-158-12-201306180-00003","article-title":"Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial","volume":"158","author":"Mahaffey","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2019.06.022_bib76","first-page":"852","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.022_bib77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.06.022_bib78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.022_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijcard.2016.02.005","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants vs warfarin in patients with atrial fibrillation and valvular heart disease","volume":"209","author":"Noseworthy","year":"2016","journal-title":"Int J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1930443X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1930443X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:32Z","timestamp":1760107352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X1930443X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0828282X1930443X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.06.022","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}